Faeth’s PIKTOR plus paclitaxel combo gains FDA fast track status

RegulatoryPIKTOR plus paclitaxelPositive

AI Analysis

Summary

Faeth Therapeutics received FDA fast track designation for PIKTOR with paclitaxel combination to treat advanced or recurrent endometrial cancer, accelerating its development pathway.

Outcome Details

fast track designation granted

Importance:6/10

Sentiment:

0.70

FDAfast trackendometrial cancercombination therapy

Read the original article

Published by Pharmaceutical Technology on August 18, 2026 9:09 AM

Read Original